Fischer S, Wolf G, Keilhoff G, Hass P
Institute of Biology, Medical Academy of Magdeburg, Germany.
Eur J Pharmacol. 1993 Feb 23;232(1):121-4. doi: 10.1016/0014-2999(93)90736-2.
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), an agonist of the non-N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor, was used to imitate glutamate-induced brain injury. A single intracerebroventricular injection of AMPA (9 nmol; 1.7 micrograms) induced convulsive reactions and heavy neurodegeneration in the hippocampal formation. MgSO4 (600 mg/kg), administered 20 min prior to or simultaneously with AMPA exposure, was able to protect completely against this non-NMDA-induced neurotoxicity. Magnesium is suggested to be a hopeful therapeutic principle for glutamate-mediated brain disorders.
α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)是谷氨酸受体非N-甲基-D-天冬氨酸(NMDA)亚型的激动剂,被用于模拟谷氨酸诱导的脑损伤。单次脑室内注射AMPA(9纳摩尔;1.7微克)会在海马结构中引发惊厥反应和严重的神经退行性变。在暴露于AMPA前20分钟或同时给予硫酸镁(600毫克/千克)能够完全保护免受这种非NMDA诱导的神经毒性。镁被认为是治疗谷氨酸介导的脑部疾病的一种有希望的治疗原则。